Furthermore, approximately 20% of patients with THSD7A-associated MN are diagnosed with malignancy within a median time of 3 months since the diagnosis of MN, indicating that THSD7A-associated MN is related to an increased risk of malignancy. The gene discussed is THSD7A; the disease is cancer.